drugset / Trial / NCT00052468

Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer

NCT00052468 ↗

RandomizedFactorialOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether carboplatin and paclitaxel combined with gemcitabine is more effective than carboplatin and paclitaxel alone in treating ovarian epithelial or fallopian tube cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel combined with gemcitabine to see how well it works compared to paclitaxel and carboplatin alone in treating patients who have undergone surgery for ovarian epithelial or fallopian tube cancer.

Timeline

Start
2002-08
Primary completion
2009-07
Completion
2011-01

Outcome

Missed primary endpoint

paper Median PFS was 17.8 months for the TCG arm and 19.3 months for the TC arm (hazard ratio [HR], 1.18; 95% CI, 1.06 to 1.32; P = .0044). PMID 20733132 ↗

paper The addition of gemcitabine to carboplatin plus paclitaxel increased treatment burden, reduced PFS time, and did not improve OS PMID 20733132 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Gemcitabine Small molecule 800 mg/m2 Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous